DK3484865T3 - Somatostatinmodulatorer og anvendelser deraf - Google Patents
Somatostatinmodulatorer og anvendelser deraf Download PDFInfo
- Publication number
- DK3484865T3 DK3484865T3 DK17828375.0T DK17828375T DK3484865T3 DK 3484865 T3 DK3484865 T3 DK 3484865T3 DK 17828375 T DK17828375 T DK 17828375T DK 3484865 T3 DK3484865 T3 DK 3484865T3
- Authority
- DK
- Denmark
- Prior art keywords
- somatostatin modulators
- somatostatin
- modulators
- Prior art date
Links
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229960000553 somatostatin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662362493P | 2016-07-14 | 2016-07-14 | |
| US201662411338P | 2016-10-21 | 2016-10-21 | |
| PCT/US2017/041694 WO2018013676A1 (en) | 2016-07-14 | 2017-07-12 | Somatostatin modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3484865T3 true DK3484865T3 (da) | 2022-10-31 |
Family
ID=60941935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17828375.0T DK3484865T3 (da) | 2016-07-14 | 2017-07-12 | Somatostatinmodulatorer og anvendelser deraf |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US9896432B2 (da) |
| EP (2) | EP4163276A1 (da) |
| JP (2) | JP6967577B2 (da) |
| KR (2) | KR102324042B1 (da) |
| CN (2) | CN109715612B (da) |
| AU (2) | AU2017296392B2 (da) |
| CA (1) | CA3030423A1 (da) |
| DK (1) | DK3484865T3 (da) |
| ES (1) | ES2931472T3 (da) |
| HR (1) | HRP20221279T1 (da) |
| HU (1) | HUE060182T2 (da) |
| IL (1) | IL264178B2 (da) |
| LT (1) | LT3484865T (da) |
| MX (1) | MX390120B (da) |
| NZ (1) | NZ750174A (da) |
| PL (1) | PL3484865T3 (da) |
| PT (1) | PT3484865T (da) |
| RS (1) | RS63776B1 (da) |
| SG (1) | SG11201900349VA (da) |
| SM (1) | SMT202200465T1 (da) |
| TW (1) | TWI789355B (da) |
| UA (1) | UA125393C2 (da) |
| WO (1) | WO2018013676A1 (da) |
| ZA (1) | ZA201900317B (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200465T1 (it) | 2016-07-14 | 2023-01-13 | Crinetics Pharmaceuticals Inc | Modulatori della somatostatina e loro usi |
| SG11201908512YA (en) | 2017-03-16 | 2019-10-30 | Crinetics Pharmaceuticals Inc | Somatostatin modulators and uses thereof |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| CN111868049B (zh) | 2018-01-17 | 2023-06-30 | 克林提克斯医药股份有限公司 | 制备促生长素抑制素调节剂的方法 |
| MA51840A (fr) * | 2018-02-12 | 2021-05-19 | Crinetics Pharmaceuticals Inc | Modulateurs de somatostatine et leurs utilisations |
| US12172991B2 (en) * | 2018-05-29 | 2024-12-24 | Council Of Scientific & Industrial Research | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof |
| FI3853218T3 (fi) | 2018-09-18 | 2025-04-15 | Crinetics Pharmaceuticals Inc | Somatostatiinin modulaattoreita ja niiden käyttöjä |
| JP2022540922A (ja) * | 2019-07-17 | 2022-09-20 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| TWI841768B (zh) | 2019-08-14 | 2024-05-11 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| CN116456968B (zh) | 2020-09-09 | 2026-03-20 | 克林提克斯医药股份有限公司 | 生长抑素调节剂的制剂 |
| JP2024506715A (ja) | 2021-02-17 | 2024-02-14 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| WO2022251212A2 (en) * | 2021-05-25 | 2022-12-01 | Crinetics Pharmaceuticals, Inc. | Uses of a somatostatin modulator for the treatment of disease |
| CN117836340A (zh) | 2021-09-28 | 2024-04-05 | 电化株式会社 | 氯丁二烯系嵌段共聚物、胶乳、胶乳组合物、以及橡胶组合物 |
| MX2024008598A (es) * | 2022-01-11 | 2024-07-23 | Crinetics Pharmaceuticals Inc | Usos de un modulador de somatostatina para el tratamiento del sindrome carcinoide. |
| WO2023238112A1 (en) | 2022-06-10 | 2023-12-14 | Assia Chemical Industries Ltd. | Solid state forms of paltusotine and process for preparation thereof |
| AU2023366475A1 (en) * | 2022-10-28 | 2025-05-29 | Exelixis, Inc. | Somatostatin receptor 2 agonists and uses thereof |
| KR20250117433A (ko) | 2022-12-13 | 2025-08-04 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 아형-2 수용체(sst2r) 표적 치료제 및 이의 용도 |
| EP4687898A1 (en) | 2023-03-28 | 2026-02-11 | Crinetics Pharmaceuticals, Inc. | Compositions and methods for administering paltusotine to patients with hepatic impairment |
| TW202523316A (zh) * | 2023-11-22 | 2025-06-16 | 美商克林提克斯醫藥股份有限公司 | 生長抑制素亞型3受器（sstr3）激動劑及其用途 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1035154A (en) | 1910-05-16 | 1912-08-13 | Ernest G Clark | Machine for rectifying perforated music and masters. |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| CA2468159A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| KR100659428B1 (ko) * | 2002-02-04 | 2006-12-19 | 에프. 호프만-라 로슈 아게 | Ｎｐｙ 길항제로서의 퀴놀린 유도체 |
| US7767817B2 (en) | 2003-09-05 | 2010-08-03 | Binghe Wang | Water soluble boronic acid fluorescent reporter compounds and methods of use thereof |
| EP1773343A4 (en) * | 2004-07-13 | 2009-05-13 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
| US20060183763A1 (en) | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| AU2006322051B2 (en) | 2005-12-05 | 2011-09-29 | Xenoport, Inc. | Levodopa prodrug mesylate, compositions thereof, and uses thereof |
| US20070265270A1 (en) | 2006-02-21 | 2007-11-15 | Hitchcock Stephen A | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009529060A (ja) | 2006-03-08 | 2009-08-13 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのキノリン及びイソキノリン誘導体 |
| US20090258853A1 (en) | 2006-03-13 | 2009-10-15 | Brian Eastman | Somatostatin Agonists |
| BRPI0918496A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | composto inibidor bicíclico de quinase, uso do mesmo, composição farmacêutica e método para inibir a atividade da quinase pim em uma célula |
| GB0818241D0 (en) | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| SG187633A1 (en) * | 2010-07-30 | 2013-03-28 | Oncotherapy Science Inc | Quinoline derivatives and melk inhibitors containing the same |
| US9884828B2 (en) | 2011-05-23 | 2018-02-06 | Imago Pharmaceuticals, Inc. | Substituted cinnolines as inhibitors of LRRK2 kinase activity |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| DE102011113749A1 (de) | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
| EP2763675A2 (en) | 2011-10-05 | 2014-08-13 | Mapi Pharma Limited | Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids |
| US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
| WO2014062667A1 (en) * | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror-gamma-t |
| CN105593221B (zh) | 2013-09-30 | 2017-09-22 | 小野药品工业株式会社 | 具有生长抑素受体激动活性的化合物及其药物用途 |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| CA2943643A1 (en) | 2014-03-24 | 2015-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| EP3317277B1 (en) | 2015-07-01 | 2021-01-20 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| US9902703B2 (en) | 2015-07-01 | 2018-02-27 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| SG11201804170RA (en) | 2015-12-17 | 2018-06-28 | Merck Patent Gmbh | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
| EP3481825A1 (en) | 2016-07-07 | 2019-05-15 | Plantex Ltd. | Solid state forms of palbociclib dimesylate |
| SMT202200465T1 (it) * | 2016-07-14 | 2023-01-13 | Crinetics Pharmaceuticals Inc | Modulatori della somatostatina e loro usi |
| CN111868049B (zh) | 2018-01-17 | 2023-06-30 | 克林提克斯医药股份有限公司 | 制备促生长素抑制素调节剂的方法 |
| FI3853218T3 (fi) | 2018-09-18 | 2025-04-15 | Crinetics Pharmaceuticals Inc | Somatostatiinin modulaattoreita ja niiden käyttöjä |
| JP2022540922A (ja) | 2019-07-17 | 2022-09-20 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチンモジュレーターの結晶形態 |
| CN116456968B (zh) | 2020-09-09 | 2026-03-20 | 克林提克斯医药股份有限公司 | 生长抑素调节剂的制剂 |
-
2017
- 2017-07-12 SM SM20220465T patent/SMT202200465T1/it unknown
- 2017-07-12 RS RS20221103A patent/RS63776B1/sr unknown
- 2017-07-12 JP JP2019500810A patent/JP6967577B2/ja active Active
- 2017-07-12 PT PT178283750T patent/PT3484865T/pt unknown
- 2017-07-12 SG SG11201900349VA patent/SG11201900349VA/en unknown
- 2017-07-12 EP EP22194733.6A patent/EP4163276A1/en not_active Withdrawn
- 2017-07-12 IL IL264178A patent/IL264178B2/en unknown
- 2017-07-12 KR KR1020197004427A patent/KR102324042B1/ko active Active
- 2017-07-12 MX MX2019000588A patent/MX390120B/es unknown
- 2017-07-12 AU AU2017296392A patent/AU2017296392B2/en active Active
- 2017-07-12 HU HUE17828375A patent/HUE060182T2/hu unknown
- 2017-07-12 PL PL17828375.0T patent/PL3484865T3/pl unknown
- 2017-07-12 HR HRP20221279TT patent/HRP20221279T1/hr unknown
- 2017-07-12 CN CN201780056677.9A patent/CN109715612B/zh active Active
- 2017-07-12 ES ES17828375T patent/ES2931472T3/es active Active
- 2017-07-12 LT LTEPPCT/US2017/041694T patent/LT3484865T/lt unknown
- 2017-07-12 CN CN202211105259.3A patent/CN115557929A/zh active Pending
- 2017-07-12 CA CA3030423A patent/CA3030423A1/en active Pending
- 2017-07-12 WO PCT/US2017/041694 patent/WO2018013676A1/en not_active Ceased
- 2017-07-12 DK DK17828375.0T patent/DK3484865T3/da active
- 2017-07-12 KR KR1020217035692A patent/KR20210134838A/ko not_active Ceased
- 2017-07-12 NZ NZ750174A patent/NZ750174A/en unknown
- 2017-07-12 US US15/647,758 patent/US9896432B2/en active Active
- 2017-07-12 EP EP17828375.0A patent/EP3484865B1/en active Active
- 2017-07-12 UA UAA201901274A patent/UA125393C2/uk unknown
- 2017-07-14 TW TW106123557A patent/TWI789355B/zh active
- 2017-12-20 US US15/849,409 patent/US10351547B2/en active Active
-
2019
- 2019-01-16 ZA ZA2019/00317A patent/ZA201900317B/en unknown
- 2019-05-08 US US16/407,031 patent/US10597377B2/en active Active
- 2019-12-12 US US16/712,620 patent/US10875839B2/en active Active
-
2020
- 2020-10-26 US US17/080,358 patent/US11414397B2/en active Active
- 2020-11-24 AU AU2020277122A patent/AU2020277122A1/en not_active Abandoned
-
2021
- 2021-10-22 JP JP2021173304A patent/JP2022028675A/ja not_active Ceased
-
2022
- 2022-07-01 US US17/810,497 patent/US20220380337A1/en not_active Abandoned
-
2025
- 2025-04-25 US US19/189,671 patent/US20260008767A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3484865T3 (da) | Somatostatinmodulatorer og anvendelser deraf | |
| DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3480213T3 (da) | Syntac-polypeptider og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3303379T3 (da) | Tigit-bindende midler og anvendelser deraf | |
| DK3268470T3 (da) | Transposasepolypeptider og anvendelser deraf | |
| DK3189081T3 (da) | Cd123-bindende midler og anvendelser deraf | |
| DK3264955T3 (da) | Blandeanordning og fremgangsmåde | |
| DK3302431T3 (da) | Taxanpartikler og anvendelse deraf | |
| DK3559227T3 (da) | Proteasevarianter og anvendelser deraf | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3402821T5 (da) | Psma-bindende antistof og anvendelser deraf | |
| DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3490988T3 (da) | Ny forbindelse og fremgangsmåde | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3853218T3 (da) | Somatostatinmodulatorer og anvendelser deraf | |
| DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3417058T3 (da) | Sortase-modificerede molekyler og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3414420T3 (da) | Brøndanordning og brøndsystem | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf |